Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Over 25 lung cancer therapeutic antibodies are currently in development says new researchPiribo, the online destination for Pharma intelligence, has added a new report.
By: Joe Walsh http://www.pharmaceutical- Patient needs and the high burden of lung cancer on society drive the development of new therapies. While advances have been seen in diagnosis and treatments (surgery, radiotherapy, chemotherapy and targeted drugs), new therapies that build on the capabilities of existing approaches are urgently required. Today, developments continue to be made in drug treatments for lung cancer; in chemotherapy, new drug combinations, and targeted molecules. More than 25 candidate therapeutic antibodies are in development or are being evaluated for the treatment of lung cancer, most of which are already in clinical trials. This field is also showing substantial innovation and these molecules are being directed at 17 different targets. This report gives an overview of the status and clinical findings of these candidate vaccines, together with developmental and market-related perspectives in this field. The report “Lung Cancer Therapeutic Antibodies” is available from Piribo at: http://www.pharmaceutical- Piribo product ID: BPR00021 About Piribo Piribo is the source for information products concerning the global biotechnology and pharmaceutical industries. Here you can browse and buy thousands of business information studies, market reports and books. Piribo has ongoing relationships with leading market research and publishing companies, so we can offer you a current and comprehensive range of specialised intelligence. # # # About Piribo. Piribo http:www.piribo.com is the source for information products concerning the global biotechnology and pharmaceutical industries. Here you can browse and buy thousands of business information studies, market reports and books. End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|